Related Experiment Video
Updated: Mar 17, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
Published on: May 17, 2019
Reducing prostaglandin E2 production to raise cancer immunogenicity
Santiago Zelenay1, Caetano Reis e Sousa2
1Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester , Manchester, UK.
None:
Cyclooxygenases (COX), commonly upregulated in numerous cancers, generate prostaglandin E2 (PGE2), which has been implicated in key aspects of malignant growth including proliferation, invasion and angiogenesis. Recently, we showed that production of PGE2 by cancer cells dominantly enables progressive tumor growth via immune escape and that cyclooxygenase inhibitors synergize with immunotherapy to enhance tumor eradication.
Related Concept Videos
Tumor Immunotherapy
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment

